

|                                 |   |                               | Phase 1 | Phase 2 | Phase 3 |
|---------------------------------|---|-------------------------------|---------|---------|---------|
| Neurology                       |   |                               |         |         |         |
| valbenazine*                    | Sprinkle Formulation  | VMAT2 Inhibitor               |         |         |         |
| valbenazine*                    | Dyskinetic Cerebral Palsy                                     | VMAT2 Inhibitor               |         |         |         |
| NBI-827104§                     | Rare Pediatric Epilepsy: EE-CSWS                              | Ca <sub>v</sub> 3.1, 3.2, 3.3 |         |         |         |
| NBI-921352##                    | Rare Pediatric Epilepsy: SCN8A-DEE                            | Na <sub>v</sub> 1.6           |         |         |         |
| NBI-1076986§§                   | Movement Disorders  | M4 Antagonist                 |         |         |         |
| Neuroendocrinology              |   |                               |         |         |         |
| crinecerfont†                   | Congenital Adrenal Hyperplasia in Adults                      | CRF <sub>1</sub>              |         |         |         |
| crinecerfont†                   | Congenital Adrenal Hyperplasia in Children & Adolescents      | CRF <sub>1</sub>              |         |         |         |
| modified-release hydrocortisone | Adrenal Insufficiency   | GC Receptor                   |         |         |         |
| modified-release hydrocortisone | Congenital Adrenal Hyperplasia                                | GC Receptor                   |         |         |         |
| Neuropsychiatry                 |   |                               |         |         |         |
| valbenazine*                    | Adjunctive Treatment of Schizophrenia                         | VMAT2 Inhibitor               |         |         |         |
| NBI-1065845¶                    | Inadequate Response to Treatment in Major Depressive Disorder | AMPA                          |         |         |         |
| luvadaxistat¶                   | Cognitive Impairment Associated with Schizophrenia            | DAAO                          |         |         |         |
| NBI-1117568††                   | Schizophrenia   | M4 Agonist                    |         |         |         |
| NBI-1070770¶,‡‡                 | Major Depressive Disorder                                     | NMDA NR2B NAM                 |         |         |         |
| NBI-1117570††                   | CNS Indications   | M1/M4 Agonist                 |         |         |         |
| NBI-1117569††                   | CNS Indications   | M4 Preferring Agonist         |         |         |         |
| NBI-1117567††,**,               | CNS Indications   | M1 Preferring Agonist         |         |         |         |
| NBI-1065890                     | CNS Indications   | VMAT2 Inhibitor               |         |         |         |

EE-CSWS = Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep.  
 SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome.  
 Neurocrine Biosciences has global rights, unless otherwise noted.  
 Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

\* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.  
 § Licensed from Idorsia Ltd.  
 ## Licensed from Xenon Pharmaceuticals, Inc.  
 † Licensed from Sanofi.

¶ Licensed from Takeda Pharmaceutical Company Limited.  
 †† Licensed from Sosei Heptares.  
 \*\*\* Sosei Heptares has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.

|| Phase 1 Initiating.  
 ‡‡ Phase 2 Initiating.  
 §§ CTA Submitted.